IndraLab

Statements

TP53 activates USP9X. 1 / 1

| 1

reach

"In conclusion, the present study confirms that WP1130 co-treatment increases cisplatin cytotoxicity by stabilizing p53 and reducing p53 ubiquitination mediated degradation in a USP9X dependent manner."

28446729

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

TP53 activates USP9X. 1 / 1

INDRA sources:

Databases

Reading